Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research UK appoints new head of public affairs and campaigning

Layla Theiner will drive the charity’s public affairs and campaigning activities across the UK and EU

Cancer Research UK has promoted Layla Theiner from EU public affairs manager to head of public affairs and campaigning.

Reporting to head of policy Sara Osborne, Theiner's new role will involve driving the charity's public affairs and campaigning activities across the UK and EU. 

During her time as EU public affairs manager, which commenced in 2010, Theiner developed the charity's EU public affairs strategy and was responsible for communicating its position on EU legislation, while also influencing and improving relevant policy.

She has experience working with politicians, advisers and civil servants around issues such as clinical trial regulation, support for cancer research and packaging of tobacco products.

Theiner also set up the EU-UK Health and Science Policy Group, which comprises of 15 representatives from medical research charities and other organisations in the UK.

Prior to joining the charity, Theiner worked as a senior associate for APCO Worldwide, a consultant at Lexington Communications and an account executive at Citigate Public Affairs.

14th November 2012

From: Marketing, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics